Methylenetetrahydrofolate Reductase Gene Polymorphisms and Cardiovascular Diseases

A growing body of evidence suggests that mutations in MTHFR gene are involved in cardiovascular diseases (CVD) cardiac development, atherosclerosis, myocardial infarction, heart failure, hypertension, aneurysmsand several other diseasecancers, neurological and metabolic disorders. Genetic variations in other genes are added risk for CVDa leading cause of morbidity and mortality around the globe. Accumulating data over the decade has enhanced our understanding of MTHFR deficiency and diseases associated risk. The frequency of MTHFR 677 C→T and 1298 A→C gene mutations varies substantially in different regions of the world among different racial and ethnic groups. In particular, 677C→T and 1298 A→C variant are associated with clinical manifestation of almost all noncommunicable diseases. This review describes the roles of MTHFR gene mutation in CVD and prospective therapies for heart disease treatment. *Corresponding author: Mohammad Afaque Alam, Department of Pediatrics, College of Medicine, Drexel University, 894 Union Ave, Memphis,, TN 38103, USA, Tel: +1-901-518-6443; E-mail: [email protected] Received May 09, 2016; Accepted May 13, 2016; Published May 21, 2016 Citation: Alam MA (2016) Methylenetetrahydrofolate Reductase Gene Polymorphisms and Cardiovascular Diseases. Cell Dev Biol 5: 172. doi:10.4172/2168-9296.1000172 Copyright: © 2016 Alam MA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.